Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 676-684 , December 2009

Second-line therapy for advanced pancreatic cancer: A review of the literature and future directions

Received 20 July 2009 ,Accepted 25 August 2009.

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225–249
  2. Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol. 2002;29:9–16
  3. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413
  4. Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM–CAP) in patients with advanced pancreatic cancer. Eur J Cancer 2005;3 [abstract PS11].
  5. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–3516
  6. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966
  7. Nakachi K, Furuse J, Ishii H, Suzuki E, Yoshino M. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol. 2007;37:114–120
  8. Boeck S, Heinemann V. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol. 2008;4:41–50
  9. Gansl RC, Reis PT, Tabacof J, et al. Pretreatment level of CA 19.9 is a prognostic factor in advanced pancreatic cancer treated with chemotherapy. J Clin Oncol 2008;26 [abstract 15637].
  10. Maréchal R, Demols A, Gay F, et al. Prognostic factors and prognostic index for chemonäive and gemcitabine-refractory patients with advanced pancreatic cancer. Oncology. 2007;73:41–51
  11. Squadroni M, Berardi R, Tummarello D, et al. CA 19.9 as an early predictor of response to first-and second-line treatment in patients with pancreatic cancer. J Clin Oncol 2008;26 [abstract 15547].
  12. Herrmann C, Abel U, Stremmel W, Jaeger D, Herrmann T. Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer. Oncology. 2007;73:335–339
  13. Boeck S, Hinke A, Wilkowski R, Heinemann V. Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol. 2007;13:224–227
  14. Oettle H, Pelzer U, Stieler J, et al. Oxaliplatin/folinic acid/5-fluoruracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 2005;23:315s [abstract 4031].
  15. Burris HA, Rivkin S, Reynolds R, et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist. 2005;10:183–190
  16. Jacobs AD, Burris HA, Rivkin S, et al. A randomized Phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer. Report from a North-American multi-center study. J Clin Oncol 2004;22:14s [abstract 4013].
  17. Boeck S, Weigang-Köhler K, Fuchs M, et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol. 2007;18:745–751
  18. Ulrich-Pur H, Raderer M, Kornek GV, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer. 2003;88:1180–1184
  19. Oettle H, Arnold D, Esser M, Huhn D, Riess H. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs. 2000;11:635–638
  20. Moore MJ, Tang P, Renouf D. A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer. J Clin Oncol 2009;27 [abstract e15634].
  21. Androulakis N, Syrigos K, Polyzos A, et al. Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest. 2005;23:9–12
  22. Boeck S, Wilkowski R, Bruns CL, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology. 2007;73:221–227
  23. Morizane C, Okusaka T, Furuse J, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009;63:313–319
  24. Miller KD, Picus J, Blanke C, et al. Phase II study of the multitargeted antifolate LY231514 (ALIMTA®, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol. 2000;11:101–103
  25. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005;16:1639–1645
  26. Riess H, Pelzer U, Stieler J, et al. A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer-CONKO 003. J Clin Oncol 2007;25:18s [abstract 4517].
  27. Pelzer U, Kubica K, Stieler J, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008;26(15s):217s [abstract 4508].
  28. Tsavaris N, Kosmas C, Skopelitis H, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs. 2005;23:369–375
  29. Gebbia V, Maiello E, Giuliani F, et al. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX-4 regimen in clinical practice. Ann Oncol 2007;18:vi 124–7.
  30. Hwang JY, Yoo C, Kim T, et al. A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy. J Clin Oncol 2009;27:15s [abstract 4618].
  31. Mitry E, Ducreux M, Ould-Kaci M, et al. Oxaliplatin combined with 5-FU in second-line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. Gastroenterol Clin Biol 2006;357–63.
  32. Boxberger F, Happich K, Schirner I, et al. Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma. Z Gastroenterol. 2002;40:881–884
  33. Demols A, Peeters M, Polus M, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer. 2006;94:481–485
  34. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. A phase II trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008;113:2046–2052
  35. Sancho A, López-Vivanco G, Díaz de Corchera I, et al. Oxaliplatin and capecitabine alter gemcitabine failure in patients with advanced pancreatic, biliary and gallbladder adenocarcinoma (APBC). J Clin Oncol 2008;28 [abstract 15606].
  36. Gasent Blesa J, Alberola Candel V, Giner Marco V. Phase II trial of second-line chemotherapy in metastatic pancreas cancer with the combination of oxaliplatin (Ox) and capecitabine (Cp). J Clin Oncol 2009;27 [abstract 15561].
  37. Cantore M, Rabbi C, Fiorentini G, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology. 2004;67:93–97
  38. Mazzer M, Zanon E, Foltran L, et al. Second-line pemetrexed-oxaliplatin for advanced pancreatic adenocarcinoma. J Clin Oncol 2009;27 [abstract 15597].
  39. Reni M, Pasetto L, Aprile G, et al. Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer. 2006;94:785–791
  40. Stathopoulos GP, Boulikas T, Vougiouka M, et al. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I–II study. Oncol Rep. 2006;15:1201–1204
  41. Kozuch P, Grossbard ML, Barzdins A, et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncross resistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist. 2001;6:488–495
  42. Togawa A, Yoshitomi H, Ito H, et al. Treatment with an oral fluoropyrimidine, S-1, plus cisplatin, in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study. Int J Clin Oncol. 2007;12:268–273
  43. Fine RL, Fogelman DR, Schreibman SM, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2008;61:167–175
  44. Reni M, Panucci MG, Passoni P, et al. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest. 2004;22:688–696
  45. Lee S, Oh B, Kim B, et al. Second-line treatment with a combination of 5-fluorouracil, adriamycin and mitomycin-C (FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. J Clin Oncol 2008;26 [abstract 15558].
  46. Sharma JJ, Razvillas B, Stephens CD, Hilsenbeck SG, Sharma A, Rothenberg ML. Phase II study of flutamide as second-line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs. 1997;15:361–364
  47. Milella M, Gelibter A, Di Cosimo S, et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer. 2004;101:133–138
  48. Niijima M, Yamaguchi T, Ishihara T, et al. Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer. 2002;94:1565–1573
  49. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 1999;5:2018–2024
  50. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987–990
  51. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999;59:4356–4362
  52. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinoma. Carcinogenesis. 2000;21:139–146
  53. Moore RJ, Zweifel BS, Huevelman DM, et al. Enhanced antitumor activity by co-administration of celecoxib, the chemotherapeutic agents cyclophosphamide, 5-FU. Proc Am Assoc Cancer Res. 2000;41:409
  54. Yip-Schneider MT, Sweeney CJ, Jung SH, Crowell PL, Marshall MS. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001;298:976–985
  55. Kulke MH, Blaszowski LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007;25:4787–4792
  56. Tang P, Gill S, Au HJ, et al. Phase II trial of paclitaxel in advanced pancreatic cancer (PC). J Clin Oncol 2009;27:15s [abstract 4609].
  57. Ignatiadis M, Polyzos A, Stathopoulos GP, et al. A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology. 2006;71:159–163
  58. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000;88:2239–2245
  59. Ko, AH, Dito E, Schillinger B, et al. A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC). J Clin Oncol 2008;26 [abstract 4516].
  60. O´Reilly EM, Niedzwiecki D, Hollis DR, et al. A phase II of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. J Clin Oncol 2008;26 [abstract 4515].
  61. Dragovich T, Laheru DA, Crowley JJ, et al. Phase II trial of vatalinib in patients with advanced or metastatic pancreatic adenocarcinoma who failed gemcitabine therapy. J Clin Oncol 2008;26 [abstract 4615].
  62. Fornier MN, Rathkopf D, Shah M, et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res. 2007;13:5841–5846
  63. Carvajal RD, Shah MA, Tse A, et al. A phase II study of docetaxel (D) followed by flavopiridol (F) in advanced, gemcitabine-refractory pancreatic cancer (PC). J Clin Oncol 2008;26 [abstract 15558].
  64. Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20:1218–1249
  65. Schlieman MG, Fahy BN, Ramsamooj R, et al. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer. 2003;89:2110–2115
  66. Yamamoto S, Tomita Y, Hoshida Y, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10:2846–2850
  67. Asano T, Yao Y, Zhu J, et al. The PI 3-kinase/Akt signaling pathway is activated due to aberrant PTEN expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene. 2004;23:8571–8580
  68. Bondar VM, Sweeney-Gotsch B, Andreeff M, et al. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2002;1:989–997
  69. Asano T, Yao Y, Zhu J, et al. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun. 2005;331:295–302
  70. Ito D, Fujimoto K, Mori T, et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer. 2006;118:2337–2343
  71. Wolpin BM, Hezel AF, Abrams T, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27:193–198
  72. Javle MM, Xiong H, Reddy S, et al. Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies. J Clin Oncol 2009;27:15s [abstract 4621].
  73. Garrido-Laguna I, Rudek M, Tan A, et al. Preclinical identification of biomarkers of response to mTOR inhibitors and subsequent application in a phase II trial of sirolimus in pancreatic cancer patients refractory to gemcitabine. J Clin Oncol 2009;27:15s [abstract 4612].

☆ Center affiliate to the “Red Temática de Investigación Cooperativa (RD06/0020/0021)” and Programme “Acción Transversal del Cáncer”. Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation.

PII: S0305-7372(09)00126-1

doi: 10.1016/j.ctrv.2009.08.012

Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 676-684 , December 2009

Article Tools